Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (51-60 of 353) with videos related to

Pageof 36
Sort By:
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|May 22, 2010
Strategies for the development of new PPAR agonists in diabetesMatthew A Cavender, Stephen J Nicholls, A Michael Lincoff
Current Interventional Cardiology Reports|April 27, 2001
Update on Pharmacology for RestenosisAlbert W. Chan, Derek P. Chew, A. Michael Lincoff
Chest|July 24, 2008
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Theodore E Warkentin, Andreas Greinacher, Andreas Koster, et al.
American Journal of Hypertension|May 7, 2002
The role of spironolactone in the treatment of patients with refractory hypertensionJames Ouzan, Catherine Pérault, A Michael Lincoff, et al.
The American Journal of Cardiology|June 13, 2006
Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary interventionJason O Robertson, A Michael Lincoff, Kathy Wolski, et al.
JAMA|September 13, 2007
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trialsA Michael Lincoff, Kathy Wolski, Stephen J Nicholls, et al.
Cardiovascular Diabetology|May 19, 2016
Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysisByron J Hoogwerf, A Michael Lincoff, Angel Rodriguez, et al.
Lancet (London, England)|April 26, 2026
Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' replyJohn Deanfield, Scott S Emerson, Søren Rasmussen, et al.
Journal of Interventional Cardiology|October 18, 2003
Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport TrialsKeith Ellis, James E Tcheng, Shelly Sapp, et al.
The Journal of Invasive Cardiology|April 12, 2013
Here and now--state of the art: optimal antithrombotic strategy for percutaneous coronary intervention-panel discussionEric J Topol, Deepak L Bhatt, Charles Simonton, et al.
Pageof 36

Showing results (51-60 of 353) with videos related to

Sort By:
Pageof 36
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|May 22, 2010
Strategies for the development of new PPAR agonists in diabetesMatthew A Cavender, Stephen J Nicholls, A Michael Lincoff
Current Interventional Cardiology Reports|April 27, 2001
Update on Pharmacology for RestenosisAlbert W. Chan, Derek P. Chew, A. Michael Lincoff
Chest|July 24, 2008
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Theodore E Warkentin, Andreas Greinacher, Andreas Koster, et al.
American Journal of Hypertension|May 7, 2002
The role of spironolactone in the treatment of patients with refractory hypertensionJames Ouzan, Catherine Pérault, A Michael Lincoff, et al.
The American Journal of Cardiology|June 13, 2006
Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary interventionJason O Robertson, A Michael Lincoff, Kathy Wolski, et al.
JAMA|September 13, 2007
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trialsA Michael Lincoff, Kathy Wolski, Stephen J Nicholls, et al.
Cardiovascular Diabetology|May 19, 2016
Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysisByron J Hoogwerf, A Michael Lincoff, Angel Rodriguez, et al.
Lancet (London, England)|April 26, 2026
Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' replyJohn Deanfield, Scott S Emerson, Søren Rasmussen, et al.
Journal of Interventional Cardiology|October 18, 2003
Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport TrialsKeith Ellis, James E Tcheng, Shelly Sapp, et al.
The Journal of Invasive Cardiology|April 12, 2013
Here and now--state of the art: optimal antithrombotic strategy for percutaneous coronary intervention-panel discussionEric J Topol, Deepak L Bhatt, Charles Simonton, et al.
Pageof 36